Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

O. Moreira, Rodrigo; Arnoldi Cobas, Roberta; Coelho, Raquel

doi:10.1186/s13098-018-0327-4

Public

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

Published in Diabetology & Metabolic Syndrome • Apr 3, 2018

Authors:

Rodrigo O. Moreira

Roberta Arnoldi Cobas

Raquel Coelho

Abstract

Glycemic control has been considered a major therapeutic goal within the scope of diabetes management, as supported by robust observational and experimental evidence. However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the ...

Subject

Medicine

Liraglutide

Glycemic

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!